Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Monument test may reveal Alzheimer's early

NCT ID NCT07367880

Diagnosis Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether a simple test of naming and identifying famous landmarks can tell apart healthy older adults from those with Alzheimer's disease. Researchers will compare the performance of 220 participants (half with Alzheimer's, half without) on this monument-based task. If successful, the test could become a new screening tool for memory and naming problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Feb 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants in the MA group will be selected from among patients attending memory consultations at the CMRR at the CHU Grenoble-Alpes (active file within the department) or from among patients referred to the CMRR by a doctor not practicing at the CMRR (general practitioners or specialists such as neurologists). Healthy elderly participants will be recruited from among those accompanying patients being monitored at the CMRR.

Ages

50 to 95 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria : * Alzheimer's disease: * Age ≥ 50 years and older * Possible or probable diagnosis of Alzheimer's disease according to the revised criteria of Mac Khann et al., 2011. * Score 18≤ MMSE ≤26 * Controls: * Age ≥ 50 years and older * MMSE score ≥ 26 For all subjects * No objection from the participant Exclusion criteria * Alzheimer's disease: * Persons referred to in Articles L1121-5 to L1121-8 of the CSP * Controls: * Memory complaints * Persons referred to in Articles L1121-5 to L1121-8 of the CSP For all subjects * Significant neurological or psychiatric history * Taking psychotropic medication (neuroleptics) * Poor command of the French language, comprehension difficulties * Significant hearing or visual impairments (diplopia, nystagmus, scotoma, etc.) * Insufficient exposure to the media and/or socio-cultural knowledge (questionnaire) ; Deficit in face recognition (Benton Face Recognition Test)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Grenoble Alpes

    RECRUITING

    Grenoble, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.